100 Agencies: Entrée Health

Share this article:
From left: Roger Haskins, Chuck Wagner, Nina Manasan Greenberg, Andrew Gottfried
From left: Roger Haskins, Chuck Wagner, Nina Manasan Greenberg, Andrew Gottfried

Entrée Health isn't really in the business of tracking and celebrating milestones. But when the appeal and necessity of its primary offering sparked a huge growth spurt over the last year, the firm found that a single number was staring it in the face: 100.

At this time last year, Entrée counted fewer than 100 employees under its roof. As of late May, the agency had grown head count to the extent that managing partner Nina Manasan Greenberg wasn't certain of the exact figure.

"The cheesiest way to answer is that we were under 100 then and we're significantly over now,” she says. Still, Greenberg and the rest of the Entrée leadership team approached the surge into triple digits warily, especially after execs at other agencies warned them to “be careful about 100.”

“On some level, it's just an arbitrary number, but it's also a number that says growth is happening in ways you haven't seen it before,” Greenberg explains. “It's easy to take your eyes off the company culture, which is a big part of what got you there in the first place.”

Maintaining that agency culture—Greenberg has been known to say, affectionately, that Entrée staffers “have a certain geekiness about them”—proved among the biggest challenges the firm faced and overcame during the last 12 months. “There's nothing about the 101st employee that changed our environment at all,” managing partner Chuck Wagner says proudly. He attributes this to a range of factors, many related to the space in which Entrée plies its trade (access and reimbursement communications).

While demand from clients for such services has surged in recent years, Entrée has resisted the temptation to serve them using whoever's available at a given moment. Unlike most other agencies, it doesn't have an army of freelancers on speed-dial. “We try not to freelance this work out, because it's not something that anyone can do,” Wagner notes. “We could probably do the same amount of revenue with 50% fewer full-time people, but we don't. That's just not the best way to do it for our clients.”

But while these clients are keen to avail themselves of Entrée's access and reimbursement expertise, sometimes they need a little nudge. Greenberg describes this less as a frustration and more as something that comes with the territory. “Maybe [some clients in this space] were a little slow to embrace digital,” she acknowledges. “But rumors to the contrary notwithstanding, digital tactics work extremely well with them when you speak their language and meet them on their terms.” Wagner agrees, adding, “The overwhelming majority of linguistic expressions used to communicate access and reimbursement are used the wrong way. There's a misalignment as to what's important to people in this space.”

Judging by the firm's new-business record over the course of the last year, Entrée has figured out a way to connect those dots. Optimer Pharmaceuticals hired the firm for work around the launch of Dificid, a diarrhea drug. Novo Nordisk, which had previously worked with Entrée on a host of projects, formalized the relationship: Entrée is now the agency partner for the Novo Nordisk Managed Markets marketing group. Other clients who expanded Entrée's charge include Baxter, Alcon Pharmaceuticals, Amarin Corp. and Genentech.

“Our motto is that it's all about client love,” Wagner says. “It's all about making sure the clients feel our immediate presence and our commitment to their business.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.